Sildenafil
Tablet, Film Coated · Oral, Intravenous
Uses
1. INDICATION S AND USAGE SILDENAFIL ORAL FILM is indicated for the treatment of erectile dysfunction. SILDENAFIL ORAL FILM is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). ( 1 )
Dosage and administration
2. DOSAGE AND ADMINISTRATION Dosage For most patients, the recommended dosage is 50 mg orally, taken as needed, approximately 1 hour before sexual activity. However, SILDENAFIL ORAL FILM may be taken anywhere from 30 minutes to 4 hours before sexual activity. ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg. ( 2.1 ) Maximum recommended dosing frequency is once per day. ( 2.1 ) Dosage Modifications for Drug Interactions: Refer to the full prescribing information for recommended dosage. ( 2.2 ) Recommended Dosage in Specific Populations: Refer to the full prescribing information for recommended dosage. ( 2.3 ) Administration Administer with or without food. Place oral film directly onto the tongue where it will disintegrate and can then be swallowed with saliva without the need for water or other liquids. Do not cut or chew SILDENAFIL ORAL FILM. 2.1 Recommended Dosage For most patients, the recommended dosage is 50 mg orally administered on the tongue, taken as needed, approximately 1 hour before sexual activity. However, SILDENAFIL ORAL FILM may be taken anywhere from 30 minutes to 4 hours before sexual activity. The maximum recommended dosing frequency is once per day. Based on effectiveness and tolerability the dosage may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg, not to exceed once per day. For administration instructions, see Dosage and Administration ( 2.4 ) . 2.2 Dosage Modifications for Drug Interactions Nitrates Concomitant use of nitrates in any form is contraindicated [ see Contraindications ( 4.1 ), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 ) ]. Alpha Blockers Initiate SILDENAFIL ORAL FILM at 25 mg orally in patients on concomitant therapy with an alpha-blocker. Patients should be stable on alpha-blocker therapy prior to initiating SILDENAFIL ORAL FILM [see Warnings and Precautions ( 5.5 ), Drug Interactions ( 7.2 ), and Clinical Pharmacology ( 12.2 ) ] . For administration instructions, see Dosage and Administration ( 2.4 ) . Ritonavir The maximum recommended dose and dosing frequency is 25 mg orally taken once within a 48-hour period in ritonavir-treated patients. Concomitant administration of ritonavir increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions ( 5.6 ), Drug Interactions ( 7.4 ), and Clinical Pharmacology ( 12.3 ) ] . For administration instructions, see Dosage and Administration ( 2.4 ) . Other CYP3A4 Inhibitors The recommended starting dosage is 25 mg orally, in patients taking strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased blood levels of sildenafil by about 3-fold [see Drug Interactions ( 7.4 ) and Clinical Pharmacology ( 12.3 ) ] . For administration instructions, see Dosage and Administration ( 2.4 ) . 2.3 Recommended Dosage in Specific Populations Age G reater than 6 5 years The recommended starting dosage is 25 mg orally in patients greater than 65 years of age [see Use in Specific Populations ( 8.5 ) ]. For administration instructions, see Dosage and Administration ( 2.4 ) . Renal Impairment The recommended starting dosage is 25 mg orally, in patients with severe renal impairment (creatinine clearance less than 30 mL/minute). The recommended starting dosage is 50 mg, in patients with mild (creatinine clearance 50 to 80 mL/min) and moderate (creatinine clearance 30 to 49 mL/min) renal impairment [see Use in Specific Populations( 8.6 ) and Clinical Pharmacology ( 12.3 ) ]. For administration instructions, see Dosage and Administration ( 2.4 ) . Hepatic Impairment The recommended starting dosage is 25 mg orally in patients with any degree of hepatic impairment. In volunteers with mild and moderate degrees of hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC), and the pharmacokinetics of sildenafil in patients with severe hepatic impairment (Child-Pugh Class C) have not been studied [see Use in Specific Populations ( 8.7 ) and Clinical Pharmacology ( 12.3 ) ]. For administration instructions, see Dosage and Administration ( 2.4 ) . 2.4 Important Administration Instructions Administer SILDENAFIL ORAL FILM orally with or without food. Place the oral film directly onto the tongue, where it will disintegrate and can then be swallowed with saliva without the need for water or other liquids. Do not cut or chew SILDENAFIL ORAL FILM.
Dosage forms and strengths
3. DOSAGE FORMS AND STRENGTHS Oral Film: 25 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 25 50 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 50 75 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 75 100 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 100 Oral film: 25 mg, 50 mg, 75 mg, 100 mg of sildenafil ( 3 )
Contraindications
4. CONTRAINDICATIONS Administration of SILDENAFIL ORAL FILM to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. SILDENAFIL ORAL FILM was shown to potentiate the hypotensive effect of nitrates. ( 4.1 , 7.1 , 12.2 ) Known hypersensitivity to sildenafil or any component of oral film. ( 4.2 ) Administration with guanylate cyclase (GC) stimulators, such as riociguat. ( 4.3 ) 4.1 Nitrates Consistent with its known effects on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.1 , 12.2 ) ] , SILDENAFIL ORAL FILM potentiates the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken SILDENAFIL ORAL FILM it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [see Dosage and Administration ( 2.2 ), Drug Interactions ( 7.1 ), and Clinical Pharmacology ( 12.2 ) ]. 4.2 Hypersensitivity Reactions SILDENAFIL ORAL FILM is contraindicated in patients with a known hypersensitivity to sildenafil or any SILDENAFIL ORAL FILM component. Hypersensitivity reactions, including rash and urticaria, have been reported [see Adverse Reactions ( 6.1 )]. 4.3 Concomitant Guanylate Cyclase (GC) Stimulators Do not use SILDENAFIL ORAL FILM in patients who are using a GC stimulator, such as riociguat. PDE5 inhibitors, including SILDENAFIL ORAL FILM, may potentiate the hypotensive effects of GC stimulators.
Warnings and precautions
5. WARNINGS AND PRECAUTIONS Patients should not use SILDENAFIL ORAL FILM if sexual activity is inadvisable due to cardiovascular status. ( 5.1 ) Patients should seek emergency treatment if an erection lasts >4 hours. Use SILDENAFIL ORAL FILM with caution in patients predisposed to priapism. ( 5.2 ) Patients should stop SILDENAFIL ORAL FILM and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). SILDENAFIL ORAL FILM should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION. ( 5.3 ) Patients should stop SILDENAFIL ORAL FILM and seek prompt medical attention in the event of sudden decrease or loss of hearing. ( 5.4 ) Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. Concomitant use may lead to hypotension. ( 5.5 ) Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. In patients taking strong CYP inhibitors such as ritonavir, sildenafil exposure is increased. Decrease in SILDENAFIL ORAL FILM dosage is recommended. ( 2.2 , 5.6 ) 5.1 Cardiovascular Risk General There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including SILDENAFIL ORAL FILM should not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. The following groups of patients were not included in clinical safety and efficacy trials for sildenafil, and therefore, until further information is available, SILDENAFIL ORAL FILM is not recommended for use in the following groups: Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg) Patients with cardiac failure or coronary artery disease causing unstable angina. Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. As with other PDE5 inhibitors, SILDENAFIL ORAL FILM has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers. In healthy subjects aged 18 to 45 years, SILDENAFIL ORAL FILM 100 mg resulted in mean maximal decreases relative to placebo of 6 mmHg systolic and 3 mmHg diastolic. In healthy subjects aged 65 years and older, SILDENAFIL ORAL FILM 100 mg resulted in mean maximal decreases relative to placebo of 14 mmHg systolic and 8 mmHg diastolic [see Clinical Pharmacology ( 12.2 )]. Prior to prescribing SILDENAFIL ORAL FILM, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. 5.2 Prolonged Erection and Priapism Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil. In the event of an erection that persists longer than 4 hours, instruct the patient to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Use SILDENAFIL ORAL FILM with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). 5.3 Effects on the Eye Advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including SILDENAFIL ORAL FILM and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged 50 years and older. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies. Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions ( 6.2 ) ] . Consider whether patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence. Therefore, use PDE5 inhibitors, including SILDENAFIL ORAL FILM with caution in these patients and only when the anticipated benefits outweigh the risks.
Side effects
6. ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Cardiovascular [see Warnings and Precautions ( 5.1 )] Prolonged Erection and Priapism [see Warnings and Precautions ( 5.2 )] Effects on the Eye [see Warnings and Precautions ( 5.3 )] Hearing Loss [see Warnings and Precautions ( 5.4 )] Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [see Warnings and Precautions ( 5.5 ) ] Adverse Reactions with the Concomitant Use of Ritonavir [see Warnings and Precautions 5.6 )] Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see Warnings and Precautions ( 5.7 ) ] Effects on Bleeding [see Warnings and Precautions ( 5.8 )] The most common adverse reactions reported in clinical trials (≥ 2%) of sildenafil are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact YARAL Pharma Inc at 1-866-218-9009 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Sildenafil was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide. Over 550 patients were treated for longer than one year. In placebo-controlled clinical studies, the discontinuation rate due to adverse reactions for sildenafil (2.5%) was not significantly different from placebo (2.3%). In fixed-dose studies, the incidence of some adverse reactions increased with dose. The type of adverse events in flexible-dose studies was similar to that for fixed dose studies. At doses above the recommended dose range, adverse reactions were similar to those detailed in Table 1 but generally were reported more frequently. Table 1: Adverse Reactions Reported by ≥2% of Patients Treated with Sildenafil and More Frequent than Placebo in Fixed-Dose Clinical Studies Adverse Reaction 25 mg (n=312) 50 mg (n=511) 100 mg (n=506) Placebo (n=607) Headache 16% 21% % 28 % 7 Flushing 10% 19% 18% 2% Dyspepsia 3% 9% 17% 2% Abnormal vision† 1% 2% 11% 1% Nasal congestion 4% 4% 9% 2% Back pain 3% 4% 4% 2% Myalgia 2% 2% 4% 1% Nausea 2% 3% 3% 1% Dizziness 3% 4% 3% 2% Rash 1% 2% 3% 1% †Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light, or blurred vision. When sildenafil was taken as recommended (on an as-needed basis) in flexible-dose, placebo-controlled clinical trials of two to twenty-six weeks duration, patients took sildenafil at least once weekly, and the following adverse reactions were reported: Table 2 : Adverse Reactions Reported by ≥2% of Patients Treated with Sildenafil and More Frequent than Placebo in Flexible-Dose Clinical Studies Adverse Reaction Sildenafil N=734 Placebo N=725 Headache 16% 4% Flushing 10% 1% Dyspepsia 7% 2% Nasal Congestion 4% 2% Abnormal Vision† 3% 0% Back pain 2% 2% Dizziness 2% 1% Rash 2% 1% †Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal vision. When SILDENAFIL ORAL FILM was taken as recommended (on an as-needed basis) in a flexible-dose, placebo-controlled clinical trial of twelve weeks duration, patients took SILDENAFIL ORAL FILM at least once weekly, not more than once per day, and the following adverse reactions were reported: Table 3: Adverse Reactions Reported by ≥2% of Patients Treated with SILDENAFIL ORAL FILM and More Frequent than Placebo in a Flexible-Dose Clinical Study Adverse Reactions SILDENAFIL ORAL FILM N=354 PLACEBO N=121 Headache 11% 4% Flushing 4% 0% Dyspepsia 4% 1% Nasal Congestion 3% 0% Dizziness 2% 0% In this study, none of the patients discontinued due to adverse reactions to SILDENAFIL ORAL FILM. The following events occurred in <2% of patients in controlled clinical trials of sildenafil; a causal relationship to sildenafil is uncertain. Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful: Body as a Whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury. Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation, hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy. Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis. Hemic and Lymphatic: anemia and leukopenia. Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia. Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain, myasthenia, synovitis. Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hypesthesia. Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased. Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis.
Drug interactions
7. DRUG INTERACTIONS SILDENAFIL ORAL FILM can potentiate the hypotensive effects of nitrates, alpha blockers, and antihypertensives. ( 4.1 , 5.5 , 7.1 , 7.2 , 7.3 , 12.2 ) With concomitant use of alpha blockers, initiate SILDENAFIL ORAL FILM at 25 mg dose. ( 2.2 ) CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. ( 2.2 , 7.4 , 12.3 ) Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48- hour period. ( 2.2 , 5.6 ) Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg. ( 2.2 , 7.4 ) 7.1 Nitrates Administration of sildenafil with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated. Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil was shown to potentiate the hypotensive effects of nitrates [see Dosage and Administration ( 2.2 ), Contraindications ( 4.1 ), Clinical Pharmacology ( 12.2 ) ] . 7.2 Alpha-blockers Use caution when co-administering alpha-blockers with sildenafil because of potential additive blood pressure lowering effects. When sildenafil is co-administered with an alpha-blocker, patients should be stable on alpha blocker therapy prior to initiating sildenafil treatment and sildenafil should be initiated at the lowest dose [see Dosage and Administration ( 2.2 ),Warnings and Precautions ( 5.5 ), Clinical Pharmacology ( 12.2 ) ]. 7.3 Amlodipine When sildenafil 100 mg was co-administered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic [see Warnings and Precautions ( 5.5 ), Clinical Pharmacology ( 12.2 ) ]. 7.4 Ritonavir and other CYP3A4 inhibitors Co-administration of ritonavir, a strong CYP3A4 inhibitor, greatly increased the systemic exposure of sildenafil (11-fold increase in AUC). It is therefore recommended not to exceed a maximum single dose of 25 mg of sildenafil in a 48 hour period [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.6 ), Clinical Pharmacology ( 12.3 ) ]. Co-administration of erythromycin, a moderate CYP3A4 inhibitor, resulted in 160% and 182% increases in sildenafil Cmax and AUC, respectively. Co-administration of saquinavir, a strong CYP3A4 inhibitor, resulted in 140% and 210% increases in sildenafil Cmax and AUC, respectively. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole could be expected to have greater effects than seen with saquinavir. A starting dose of 25 mg of sildenafil should be considered in patients taking erythromycin or strong CYP3A4 inhibitors (such as saquinavir, ketoconazole, itraconazole) [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 ) ]. 7.5 Alcohol In a drug-drug interaction study of sildenafil 50 mg given with alcohol 0.5 g/kg, in which mean maximum blood alcohol levels of 0.08% was achieved, sildenafil did not potentiate the hypotensive effect of alcohol in healthy volunteers [see Clinical Pharmacology ( 12.2 ) ] .
Use in specific populations
8. USE IN SPECIFIC POPULATIONS Geriatric use: Recommended starting dose is 25 mg. ( 2.3 , 8.5 ) Severe renal impairment: Recommended starting dose is 25 mg. ( 2.3 , 8.6 ) Hepatic impairment: Recommended starting dose is 25 mg. ( 2.3 , 8.7 ) 8.1 Pregnancy Risk Summary SILDENAFIL ORAL FILM is not indicated for use in females. There are no data with the use of SILDENAFIL ORAL FILM in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m2 basis ( see Data ). Data Animal Data No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis. These doses represent, respectively, about 16 and 32 times the MRHD on a mg/m2 basis in a 50 kg subject. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m2 basis in a 50 kg subject. 8.2 Lactation Risk Summary SILDENAFIL ORAL FILM is not indicated for use in females. Limited data indicate that sildenafil and its active metabolite are present in human milk. There is no information on the effects on the breastfed child, or the effects on milk production. 8.4 Pediatric Use SILDENAFIL ORAL FILM is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients. 8.5 Geriatric Use Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years) [see Clinical Pharmacology ( 12.3 ) ] . Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [see Clinical Pharmacology ( 12.3 ) ]. Of the total number of subjects in clinical studies of sildenafil, 18% were 65 years and older, while 2% were 75 years and older. No overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger adult (< 65 years of age) subjects. Of the total number of subjects in the clinical study of SILDENAFIL ORAL FILM, 31% were 65 years and older. No overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger (< 65 years of age) subjects. A starting dose of SILDENAFIL ORAL FILM 25 mg is recommended in patients 65 years of age and older due to the higher systemic exposure in older subjects, and larger decreases in blood pressure observed in older subjects in a clinical pharmacology study [see Dosage and Administration ( 2.3 ) , Warning s and Precautions ( 5.1 ), Clinical Pharmacology ( 12.2 ] . 8.6 Renal Impairment No dose adjustment is required for mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment. In volunteers with severe renal impairment (Clcr<30 mL/min), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (~2 fold), approximately doubling of Cmax and AUC. A starting dose of 25 mg should be considered in patients with severe renal impairment [see Dosage and Administration ( 2.3 ) , Clinical Pharmacology ( 12.3 ) ] . 8.7 Hepatic Impairment In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see Dosage and Administration ( 2.3 ) , Clinical Pharmacology ( 12.3 ) ].
Pregnancy
8.1 Pregnancy Risk Summary SILDENAFIL ORAL FILM is not indicated for use in females. There are no data with the use of SILDENAFIL ORAL FILM in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m2 basis ( see Data ). Data Animal Data No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis. These doses represent, respectively, about 16 and 32 times the MRHD on a mg/m2 basis in a 50 kg subject. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m2 basis in a 50 kg subject.
Pediatric use
8.4 Pediatric Use SILDENAFIL ORAL FILM is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients.
Geriatric use
8.5 Geriatric Use Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years) [see Clinical Pharmacology ( 12.3 ) ] . Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [see Clinical Pharmacology ( 12.3 ) ]. Of the total number of subjects in clinical studies of sildenafil, 18% were 65 years and older, while 2% were 75 years and older. No overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger adult (< 65 years of age) subjects. Of the total number of subjects in the clinical study of SILDENAFIL ORAL FILM, 31% were 65 years and older. No overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger (< 65 years of age) subjects. A starting dose of SILDENAFIL ORAL FILM 25 mg is recommended in patients 65 years of age and older due to the higher systemic exposure in older subjects, and larger decreases in blood pressure observed in older subjects in a clinical pharmacology study [see Dosage and Administration ( 2.3 ) , Warning s and Precautions ( 5.1 ), Clinical Pharmacology ( 12.2 ] .
Overdosage
In studies in healthy volunteers administered single sildenafil doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but incidence rates and severities were increased. In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and it is not eliminated in the urine.
Description
(sildenafil) oral film is for treatment of erectile dysfunction and contains sildenafil citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate, has the molecular formula C 22 H 39 N 6 O 4 S ‧ C 6 H 8 O 7 , and the following structural formula: Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. SILDENAFIL ORAL FILM is formulated as an opaque light blue, thin, flexible oral film with the characteristic lemon and grapefruit scent. The product is available in four different strengths 25, 50, 75, or 100 mg of sildenafil equivalent to 35, 70, 105, 140 mg sildenafil citrate respectively for oral administration. In addition to the active ingredient, sildenafil citrate, each oral film contains the following inactive ingredients: Blue Videojet ink, FD&C Blue No.2, glycerin, grapefruit flavor, lemon flavor, maltodextrin, polysorbate 20, polyvinyl acetate dispersion, propylene glycol monocaprylate, sucralose, titanium dioxide. SILDENAFIL ORAL FILM contains no ingredient made from a gluten-containing grain (wheat, barley, or rye). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate, has the molecular formu
Mechanism of action
12.1 Mechanism of Action The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation. Binding Characteristics Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). Sildenafil is approximately 4,000-fold more selective for PDE5 compared to PDE3. PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina which is involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision [see Clinical Pharmacology ( 12.2 ) ]. In addition to human corpus cavernosum smooth muscle, PDE5 is also found in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle, brain, heart, liver, kidney, lung, pancreas, prostate, bladder, testis, and seminal vesicle. The inhibition of PDE5 in some of these tissues by sildenafil may be the basis for the enhanced platelet antiaggregatory activity of NO observed in vitro, an inhibition of platelet thrombus formation in vivo and peripheral arterial-venous dilatation in vivo .
How supplied
16 HOW SUPPLIED/STORAGE AND HANDLING SILDENAFIL ORAL FILM is supplied as oral films in individually sealed foil pouches in four dosage strengths. Each carton contains 4 or 8 pouches. The product is an opaque light blue, thin, flexible oral film with film imprint code, and characteristic lemon and grapefruit flavor with the following dimensions: Strengths (mg ) of sildenafil Film Imprint Code Film Dimensions ( shape ) NDC for Carton of 4 Pouches NDC for Carton of 8 Pouches 25 mg S25 30 mm x 15 mm (rectangular) 82347-0205-5 82347-0205-6 50 mg S50 30 mm x 30 mm (square) 82347-0210-5 82347-0210-6 75 mg S75 30 mm x 45 mm (rectangular) 82347-0215-5 82347-0215-6 100 mg S100 45 mm x 40 mm (rectangular) 82347-0220-5 82347-0220-6 Recommended Storage: Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Patient information
Advise the patient to read the FDA-approved patient labeling ( Patient Information ) Administration Instructions Advise patients to place SILDENAFIL ORAL FILM directly onto the tongue where it will disintegrate and can then be swallowed with saliva without the need for water or other liquids. Advise patients not to cut or chew SILDENAFIL ORAL FILM [see Dosage and Administration ( 2.4 ) ] . Nitrates Physicians should discuss with patients the contraindication of SILDENAFIL ORAL FILM with regular and/or intermittent use of nitric oxide donors, such as organic nitrates or organic nitrites in any form [see Contraindications ( 4.1 )]. Guanylate Cyclase (GC) Stimulators Physicians should discuss with patients the contraindication of SILDENAFIL ORAL FILM with use of guanylate cyclase stimulators such as riociguat [see Contraindications ( 4.3 )]. Concomitant Use with Drugs Which Lower Blood Pressure Physicians should advise patients of the potential for SILDENAFIL ORAL FILM to augment the blood pressure lowering effect of alpha-blockers and antihypertensive medications. Concomitant administration of SILDENAFIL ORAL FILM and an alpha blocker may lead to symptomatic hypotension in some patients. Therefore, when SILDENAFIL ORAL FILM is co-administered with alpha-blockers, patients should be stable on alpha-blocker therapy prior to initiating SILDENAFIL ORAL FILM treatment and SILDENAFIL ORAL FILM should be initiated at the lowest dose [see Warnings and Precautions ( 5.5 )]. Cardiovascular Risk Considerations Physicians should discuss with patients the potential cardiac risk of sexual activity in patients with preexisting cardiovascular risk factors. Patients who experience symptoms (e.g., angina pectoris, dizziness, nausea) upon initiation of sexual activity should be advised to refrain from further activity and should discuss the episode with their physician [see Warnings and Precautions ( 5.1 )]. Sudden Loss of Vision Physicians should advise patients to stop use of all PDE5 inhibitors, including SILDENAFIL ORAL FILM and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including possible permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors, including sildenafil. Physicians should discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye. Physicians should also discuss with patients the increased risk of NAION among the general population in patients with a “crowded” optic disc, although evidence is insufficient to support screening of prospective users of PDE5 inhibitor, including SILDENAFIL ORAL FILM, for this uncommon condition [see Warnings and Precautions ( 5.3 ) , Adverse Reactions ( 6.2 )]. Sudden Hearing Loss Physicians should advise patients to stop taking PDE5 inhibitors, including SILDENAFIL ORAL FILM and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including SILDENAFIL ORAL FILM. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Warnings and Precautions ( 5.4 ) , Adverse Reactions ( 6.2 )]. Priapism Physicians should warn patients that prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result [see Warnings and Precautions ( 5.2 )]. Avoid Use with other PDE5 Inhibitors Physicians should inform patients not to take SILDENAFIL ORAL FILM with other PDE5 inhibitors, including pulmonary arterial hypertension (PAH) treatments containing sildenafil. The safety and efficacy of SILDENAFIL ORAL FILM with other PDE5 inhibitors have not been studied [see Warnings and Precautions ( 5.7 )]. Sexually Transmitted Disease The use of SILDENAFIL ORAL FILM offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), should be considered [see Warnings and Precautions ( 5.9 )]. Distributed by: YARAL Pharma Inc., Parsippany, NJ 07054 USA
Label text from the FDA structured product label by Yaral Pharma Inc. (revised Jul 17, 2026). Long sections are shortened; the complete label is on DailyMed.
Active ingredients
- Sildenafil Citrate in 149 products
- Sildenafil in 2 products
Sildenafil NDC products (151)
| NDC | Strength & form | Labeler | Type |
|---|---|---|---|
| 50090-1766 | Sildenafil Citrate 20 mg/1 Tablet | A-S Medication Solutions | ANDA |
| 50090-7977 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 50090-7964 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 50090-7963 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 50090-6804 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 50090-5415 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 50090-5325 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 50090-5236 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 50090-5235 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | A-S Medication Solutions | ANDA |
| 0591-4050 | Sildenafil Citrate 10 mg/mL Powder, For Suspension | Actavis Pharma, Inc. | ANDA |
| 72888-015 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Advagen Pharma Ltd | ANDA |
| 72888-016 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Advagen Pharma Ltd | ANDA |
| 72888-017 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Advagen Pharma Ltd | ANDA |
| 27241-175 | Sildenafil Citrate 10 mg/mL Powder, For Suspension | Ajanta Pharma USA Inc. | ANDA |
| 27241-124 | Sildenafil Citrate 20 mg/1 Tablet | Ajanta Pharma USA Inc. | ANDA |
| 60687-788 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | American Health Packaging | ANDA |
| 65162-351 | Sildenafil Citrate 20 mg/1 Tablet | Amneal Pharmaceuticals LLC | ANDA |
| 60219-1752 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Amneal Pharmaceuticals NY LLC | ANDA |
| 60219-1751 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Amneal Pharmaceuticals NY LLC | ANDA |
| 60219-1753 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Amneal Pharmaceuticals NY LLC | ANDA |
| 60219-2651 | Sildenafil 10 mg/mL Powder, For Suspension | Amneal Pharmaceuticals NY LLC | ANDA |
| 69238-1574 | Sildenafil 10 mg/mL Powder, For Suspension | Amneal Pharmaceuticals NY LLC | ANDA |
| 53746-351 | Sildenafil Citrate 20 mg/1 Tablet | Amneal Pharmaceuticals of New York LLC | ANDA |
| 70954-168 | Sildenafil Citrate 10 mg/mL For Suspension | ANI Pharmaceuticals, Inc. | ANDA |
| 71610-675 | Sildenafil Citrate 100 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA |
| 71610-679 | Sildenafil Citrate 50 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA |
| 55801-340 | Sildenafil Citrate 100 mg/1 Tablet | Appco Pharma LLC | ANDA |
| 55801-339 | Sildenafil Citrate 50 mg/1 Tablet | Appco Pharma LLC | ANDA |
| 55801-338 | Sildenafil Citrate 25 mg/1 Tablet | Appco Pharma LLC | ANDA |
| 76420-061 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Asclemed USA, Inc. | ANDA |
| 65862-691 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Aurobindo Pharma Limited | ANDA |
| 65862-690 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Aurobindo Pharma Limited | ANDA |
| 65862-689 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Aurobindo Pharma Limited | ANDA |
| 65862-688 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Aurobindo Pharma Limited | ANDA |
| 42291-937 | Sildenafil Citrate 20 mg/1 Tablet | AvKARE | ANDA |
| 50268-717 | Sildenafil Citrate 20 mg/1 Tablet | AvPAK | ANDA |
| 68001-597 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | BluePoint Laboratories | ANDA |
| 68001-363 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | BluePoint Laboratories | ANDA |
| 35561-253 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Bostal LLC | ANDA |
| 35561-252 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Bostal LLC | ANDA |
| 35561-251 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Bostal LLC | ANDA |
| 71335-1963 | Sildenafil Citrate 20 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 71335-1777 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 71335-1649 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 63629-7833 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 63629-5029 | Sildenafil Citrate 20 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 71335-2657 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 71335-1638 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 71335-1088 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 71335-1005 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 71335-0969 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 72162-2363 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 71335-1028 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Bryant Ranch Prepack | ANDA |
| 71209-108 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Cadila Pharmaceuticals Limited | ANDA |
| 71209-106 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Cadila Pharmaceuticals Limited | ANDA |
| 71209-107 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Cadila Pharmaceuticals Limited | ANDA |
| 31722-710 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Camber Pharmaceuticals, Inc. | ANDA |
| 31722-709 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Camber Pharmaceuticals, Inc. | ANDA |
| 31722-136 | Sildenafil Citrate 10 mg/mL For Suspension | Camber Pharmaceuticals, Inc. | ANDA |
| 31722-711 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Camber Pharmaceuticals, Inc. | ANDA |
| 31722-776 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Camber Pharmaceuticals, Inc. | ANDA |
| 31722-965 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Camber Pharmaceuticals, Inc. | ANDA |
| 31722-967 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Camber Pharmaceuticals, Inc. | ANDA |
| 31722-966 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Camber Pharmaceuticals, Inc. | ANDA |
| 55154-4307 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Cardinal Health 107, LLC | ANDA |
| 62135-372 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Chartwell RX, LLC | ANDA |
| 69097-951 | Sildenafil Citrate 25 mg/1 Tablet | CIPLA USA INC., | ANDA |
| 69097-952 | Sildenafil Citrate 50 mg/1 Tablet | CIPLA USA INC., | ANDA |
| 69097-953 | Sildenafil Citrate 100 mg/1 Tablet | CIPLA USA INC., | ANDA |
| 72189-069 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | DIRECT RX | ANDA |
| 72189-298 | Sildenafil Citrate 20 mg/1 Tablet | DirectRx | ANDA |
| 55150-166 | Sildenafil Citrate 10 mg/12.5mL Injection, Solution | Eugia US LLC | ANDA |
| 76282-645 | Sildenafil Citrate 100 mg/1 Tablet | Exelan Pharmaceuticals, Inc. | ANDA |
| 76282-644 | Sildenafil Citrate 50 mg/1 Tablet | Exelan Pharmaceuticals, Inc. | ANDA |
| 76282-643 | Sildenafil Citrate 25 mg/1 Tablet | Exelan Pharmaceuticals, Inc. | ANDA |
| 51407-987 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Golden State Medical Supply, Inc. | ANDA |
| 72303-0845 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | HEC Pharm USA Inc. | ANDA |
| 72303-0846 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | HEC Pharm USA Inc. | ANDA |
| 72303-0847 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | HEC Pharm USA Inc. | ANDA |
| 59746-471 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Jubilant Cadista Pharmaceuticals Inc. | ANDA |
| 59746-436 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Jubilant Cadista Pharmaceuticals Inc. | ANDA |
| 59746-435 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Jubilant Cadista Pharmaceuticals Inc. | ANDA |
| 59746-434 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Jubilant Cadista Pharmaceuticals Inc. | ANDA |
| 68180-283 | Sildenafil Citrate 10 mg/mL Powder, For Suspension | Lupin Pharmaceuticals, Inc. | ANDA |
| 33342-042 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Macleods Pharmaceuticals Limited | ANDA |
| 33342-536 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Macleods Pharmaceuticals Limited | ANDA |
| 33342-041 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Macleods Pharmaceuticals Limited | ANDA |
| 33342-121 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Macleods Pharmaceuticals Limited | ANDA |
| 33342-043 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Macleods Pharmaceuticals Limited | ANDA |
| 0904-6671 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Major Pharmaceuticals | ANDA |
| 72241-071 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Modavar Pharmaceuticals LLC | ANDA |
| 72241-070 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Modavar Pharmaceuticals LLC | ANDA |
| 72241-069 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Modavar Pharmaceuticals LLC | ANDA |
| 51655-468 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Northwind Health Company, LLC | ANDA |
| 51655-172 | Sildenafil Citrate 20 mg/1 Tablet | Northwind Health Company, LLC | ANDA |
| 68071-2072 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals, Inc. | ANDA |
| 68071-3978 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals, Inc. | ANDA |
| 68071-3954 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals, Inc. | ANDA |
| 68071-3832 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals, Inc. | ANDA |
| 68071-3745 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals, Inc. | ANDA |
| 68071-3743 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals, Inc. | ANDA |
| 68071-2537 | Sildenafil Citrate 20 mg/1 Tablet | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-5115 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-4674 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-4617 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-4599 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-4517 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-3908 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-2985 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-2602 | Sildenafil Citrate 20 mg/1 Tablet | NuCare Pharmaceuticals,Inc. | ANDA |
| 68071-2213 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | NuCare Pharmaceuticals,Inc. | ANDA |
| 72789-098 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | PD-Rx Pharmaceuticals, Inc. | ANDA |
| 43063-982 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | PD-Rx Pharmaceuticals, Inc. | ANDA |
| 72789-103 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | PD-Rx Pharmaceuticals, Inc. | ANDA |
| 68788-7974 | Sildenafil Citrate 20 mg/1 Tablet | Preferred Pharmaceuticals Inc. | ANDA |
| 68788-7879 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Preferred Pharmaceuticals, Inc. | ANDA |
| 82804-185 | Sildenafil Citrate 20 mg/1 Tablet | Proficient Rx LP | ANDA |
| 82804-243 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 71205-509 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 63187-619 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 63187-789 | Sildenafil Citrate 20 mg/1 Tablet | Proficient Rx LP | ANDA |
| 63187-813 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 71205-088 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 71205-267 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 71205-220 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 71205-473 | Sildenafil Citrate 100 mg/1 Tablet | Proficient Rx LP | ANDA |
| 71205-498 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 71205-542 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Proficient Rx LP | ANDA |
| 82009-094 | Sildenafil Citrate 20 mg/1 Tablet | Quallent Pharmaceuticals Health LLC | ANDA |
| 70518-4596 | Sildenafil Citrate 20 mg/1 Tablet | REMEDYREPACK INC. | ANDA |
| 70518-3433 | Sildenafil Citrate 20 mg/1 Tablet | REMEDYREPACK INC. | ANDA |
| 70518-1844 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | REMEDYREPACK INC. | ANDA |
| 82647-212 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Reyoung Corporation | ANDA |
| 82647-211 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Reyoung Corporation | ANDA |
| 82647-210 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Reyoung Corporation | ANDA |
| 0093-5341 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | Teva Pharmaceuticals USA, Inc. | ANDA |
| 0093-5342 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | Teva Pharmaceuticals USA, Inc. | ANDA |
| 0093-5343 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | Teva Pharmaceuticals USA, Inc. | ANDA |
| 13668-185 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | Torrent Pharmaceuticals Limited | ANDA |
| 52817-340 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | TruPharma LLC | ANDA |
| 52817-341 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | TruPharma LLC | ANDA |
| 52817-342 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | TruPharma LLC | ANDA |
| 69543-419 | Sildenafil Citrate 10 mg/mL For Suspension | Virtus Pharmaceuticals, LLC | ANDA |
| 72865-103 | Sildenafil Citrate 100 mg/1 Tablet, Film Coated | XLCARE Pharmaceuticals INC. | ANDA |
| 72865-102 | Sildenafil Citrate 50 mg/1 Tablet, Film Coated | XLCARE Pharmaceuticals INC. | ANDA |
| 72865-101 | Sildenafil Citrate 25 mg/1 Tablet, Film Coated | XLCARE Pharmaceuticals INC. | ANDA |
| 72865-105 | Sildenafil Citrate 20 mg/1 Tablet, Film Coated | XLCare Pharmaceuticals, Inc. | ANDA |
| 82347-0205 | Sildenafil Citrate 25 mg/1 Film | Yaral Pharma Inc. | NDA |
| 82347-0210 | Sildenafil Citrate 50 mg/1 Film | Yaral Pharma Inc. | NDA |
| 82347-0215 | Sildenafil Citrate 75 mg/1 Film | Yaral Pharma Inc. | NDA |
| 82347-0220 | Sildenafil Citrate 100 mg/1 Film | Yaral Pharma Inc. | NDA |
Frequently asked questions
What is Sildenafil used for?
1. INDICATION S AND USAGE SILDENAFIL ORAL FILM is indicated for the treatment of erectile dysfunction. SILDENAFIL ORAL FILM is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). ( 1 )
What are the side effects of Sildenafil?
6. ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Cardiovascular [see Warnings and Precautions ( 5.1 )] Prolonged Erection and Priapism [see Warnings and Precautions ( 5.2 )] Effects on the Eye [see Warnings and Precautions ( 5.3 )] Hearing Loss [see Warnings and Precautions ( 5.4 )] Hypotension when Co-administered with Alpha-blockers or… See the full label for the complete list.
Who makes Sildenafil?
Sildenafil is listed by 51 labelers in the FDA NDC directory, including A-S Medication Solutions, Actavis Pharma, Inc., Advagen Pharma Ltd, Ajanta Pharma USA Inc..